ArticleBlood2018
Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.Nature medicine · 2026Trial
- Eprenetapopt Plus Azacitidine inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Current and future therapies for acute myeloblastic leukemia.Journal of hematology & oncology · 2026Review
- Controversies in the Management of AML in Older Patients: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2026Review
- Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.Blood cancer journal · 2026Article
- A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.Blood advances · 2026Article
- Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis.Annals of medicine · 2025Article
- Article
- Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.Journal of internal medicine · 2025Review
- The TP53 tumor suppressor gene: From molecular biology to clinical investigations.Journal of internal medicine · 2025Review
- Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.Blood advances · 2025Article
- TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions.Hematological oncology · 2025Review
- Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.Leukemia & lymphoma · 2025Article
- Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Review
- Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.Bone marrow transplantation · 2025Article
- Clonal Evolution of Myeloid Malignancies Treated With Microtransplantation: A Single-Centre Experience.Journal of cellular and molecular medicine · 2025Article
- Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?Bone marrow transplantation · 2025Article
- Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications.Blood advances · 2025Article
- Prognostic impact of methylation-related gene mutations in elderly acute myeloid leukemia: a real-world retrospective analysis.Frontiers in medicine · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.